GlaxoSmithKline Egypt S.A.E. specializes in the development, manufacture and marketing of medicines. Their products are for the treatment of diabetes, asthma, cancer, hepatic viruses, infections, allergies and gastro-intestinal and cardiovascular diseases.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
09/11/26	EGP 385.00	+1.58%	1,582,397
08/11/26	EGP 379.00	+19.96%	929,268
05/11/26	EGP 315.93	+1.90%	364,073
04/11/26	EGP 310.03	+1.65%	680,040
03/11/26	EGP 305.00	+15.53%	494,893

End-of-day quote Egyptian Exchange

More quotes

End-of-day quote Egyptian Exchange 09/11/2026			5-day change	1st Jan Change
385.00 ^EGP	+1.58%		+45.83%	+504.87%

08-13	GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-17	GlaxoSmithKline Q1 consol net profit EGP 4.7 million	RE

Market Cap	32.15B 597M 533M 490M 445M 843M 55.93B 864M 5.86B 2.34B 29.94B 2.24B 2.19B 94.31B	P/E 2024	17.3x	P/E 2025	24.9x
Enterprise Value	31.76B 589M 526M 484M 439M 833M 55.24B 853M 5.79B 2.31B 29.57B 2.21B 2.16B 93.14B	EV / Sales 2024	1.02x	EV / Sales 2025	1.32x
Free-Float	2.91%	Yield 2024	2.78%	Yield 2025	1.18%

08-13	GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-17	GlaxoSmithKline Q1 consol net profit EGP 4.7 million	RE
03-12	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-12	GlaxoSmithKline FY dividend EGP 0.75 per share	RE
03-12	GlaxoSmithKline FY consol profit EGP 213.2 million	RE
12-30	GlaxoSmithKline S.A.E announces Annual dividend, payable on January 14, 2026	CI
11-19	GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	GlaxoSmithKline Q3 consol loss EGP 34.8 million	RE
12/08/25	GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
12/08/25	GlaxoSmithKline posts Q2 consol profit EGP 5.9 mln	RE
14/05/25	GlaxoSmithKline S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
14/05/25	Glaxosmithkline Reports Q1 Net Profit EGP 43.5 Million	RE
09/03/25	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2024	CI

10/03/22	GlaxoSmithKline E : Glaxo Smith Kline (BIOC.CA) - Listing Committee Decision	PU
20/12/21	GSK hires former Tesco boss Sir Dave Lewis to head up £40bn spin-off	AQ

GlaxoSmithKline S.A.E Stock

Stocks

BIOC

EGS38171C012

Pharmaceuticals

Valuation: GlaxoSmithKline S.A.E

Chart: GlaxoSmithKline S.A.E

Latest news: GlaxoSmithKline S.A.E

Press Releases: GlaxoSmithKline S.A.E

Quotes and Performance

Price Extremes

Managers and Directors: GlaxoSmithKline S.A.E

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 day	+1.58%
1 week	+45.83%
Current month	+32.44%
1 month	+16.67%
3 months	-19.33%
6 months	+434.87%
Current year	+504.87%

1 week	305	415
1 month	212.05	415
Current year	55.1	609
1 year	55.1	609
3 years	24.7	609
5 years	18.7	609
10 years	0	609

Director	Title	Age	Since
Sherine El-Ansari BRD	Director/Board Member	-	-
Ashraf Mohammed Ibrahim Mansour CHM	Chairman	-	-
Munir Ghabour Hanna BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLAXOSMITHKLINE S.A.E	+1.58%	+45.83%	+464.43%	+1,107.65%	597M
ELI LILLY AND COMPANY	+4.28%	+0.07%	+52.75%	+138.78%	1,258B
JOHNSON & JOHNSON	+2.13%	+4.27%	+51.21%	+91.36%	679B
ABBVIE INC.	+0.68%	+1.54%	+33.83%	+112.47%	518B
ROCHE HOLDING AG	-0.56%	+2.15%	+43.21%	+68.70%	390B
MERCK & CO., INC.	+1.38%	+0.27%	+72.42%	+45.30%	367B
NOVARTIS AG	+0.30%	+1.99%	+31.23%	+59.93%	307B
ASTRAZENECA PLC	-0.60%	+1.76%	+6.68%	+38.77%	293B
AMGEN INC.	+1.04%	-0.05%	+45.29%	+76.18%	252B
GILEAD SCIENCES, INC.	+1.46%	-0.59%	+42.48%	+125.82%	210B
Average	+0.54%	+3.57%	+84.35%	+186.50%	427B
Weighted average by Cap.	+0.45%	+1.18%	+45.44%	+96.94%

	2024	2025
Net sales	2.99B 55.5M 49.54M 45.59M 41.38M 78.41M 5.2B 80.36M 545M 217M 2.79B 208M 204M 8.77B	3.73B 69.23M 61.8M 56.86M 51.61M 97.81M 6.49B 100M 680M 271M 3.47B 260M 254M 10.94B
Net income	174M 3.23M 2.88M 2.65M 2.41M 4.56M 303M 4.67M 31.72M 12.64M 162M 12.12M 11.86M 510M	213M 3.96M 3.53M 3.25M 2.95M 5.59M 371M 5.73M 38.88M 15.5M 199M 14.85M 14.53M 625M
Net Debt	44.01M 817K 729K 671K 609K 1.15M 76.55M 1.18M 8.02M 3.2M 40.98M 3.07M 3M 129M	-398M -7.38M -6.59M -6.07M -5.51M -10.43M -692M -10.69M -72.56M -28.92M -371M -27.72M -27.13M -1.17B